Triglycerides: a case for treatment?

Current Opinion in Cardiology
Anthony S WierzbickiDimitri P Mikhailidis

Abstract

To discuss the relevance of triglycerides to cardiovascular disease (CVD) risk. Triglycerides are a commonly measured component of lipid profiles. Raised triglycerides are a component of the metabolic syndrome and are strongly associated with future risk of diabetes as well as cardiovascular disease. Triglyceride-rich particles form a component of cardiovascular risk above that delineated by low density lipoprotein (LDL) cholesterol. Elevated triglycerides are a marker of atherogenic small dense LDL, excess baseline and residual CVD risk even after statin therapy. Additional methods to lower triglycerides include niacin, fibrates and omega-3 fatty acids. Trials in monotherapy with both niacin and fibrates suggest some benefit in reducing CVD events based on evidence mostly derived from older studies. However, endpoint trials of adding either niacin or fenofibrate to statins have not shown any benefit, except possibly in patients with an increased atherogenic index (triglyceride : HDL-C ratio), or have been underpowered. Trials of omega-3 fatty acids have been performed at doses insufficient to affect lipid profiles in populations with inadequate control of LDL-C but did reduce CVD events. Further trials of lipid-lowering agents...Continue Reading

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Aug 1, 1992·The American Journal of Clinical Nutrition·A M Dattilo, P M Kris-Etherton
Dec 14, 1992·The American Journal of Cardiology·W P Castelli
May 1, 1992·European Journal of Epidemiology·G Assmann, H Schulte
Jan 1, 1988·Drugs·D W Bilheimer
Jan 10, 1996·JAMA : the Journal of the American Medical Association·R G Bakker-ArkemaD M Black
Jun 1, 1996·The American Journal of Cardiology·G AssmannA von Eckardstein
Apr 4, 1998·The American Journal of Cardiology·E A SteinP Laskarzewski
Jul 6, 2000·Circulation·UNKNOWN Bezafibrate Infarction Prevention (BIP) study
Jan 6, 2001·Journal of Cardiovascular Risk·H B Rubins
Apr 13, 2001·JAMA : the Journal of the American Medical Association·S J RobinsUNKNOWN VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·A S WierzbickiR Wray
Jan 18, 2005·Journal of the American College of Cardiology·Rakesh S BirjmohunErik S G Stroes
Apr 6, 2005·Journal of the American College of Cardiology·Paul N HopkinsEliot A Brinton
Oct 26, 2005·American Journal of Preventive Medicine·Ariane KönigSteven M Teutsch
Dec 22, 2005·Current Medical Research and Opinion·Eric BruckertJohn Chapman
Apr 20, 2006·International Journal of Clinical Practice·A S Wierzbicki
Oct 19, 2006·Current Atherosclerosis Reports·Margo A Denke
Feb 10, 2007·European Heart Journal·Richard M CubbonUNKNOWN Evaluation of Methods and Management of Acute Coronary Events Investigators
Mar 3, 2007·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·Sabrina E Feldeisen, Katherine L Tucker
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Dec 28, 2007·Atherosclerosis·William S HarrisErnst J Schaefer
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Aug 19, 2008·International Journal of Clinical Practice·A S Wierzbicki
Feb 10, 2009·Current Pharmaceutical Design·T D Filippatos, D P Mikhailidis
May 9, 2009·Current Opinion in Cardiology·Anthony S Wierzbicki

❮ Previous
Next ❯

Citations

Jan 8, 2014·Lipids in Health and Disease·Todd C RideoutPeter J H Jones
Mar 22, 2014·International Journal of Nanomedicine·Ruth R MagayeJinshun Zhao
Sep 10, 2013·Expert Opinion on Pharmacotherapy·Manfredi RizzoJose Lopez-Miranda
Oct 30, 2013·Current Medical Research and Opinion·Niki KatsikiDimitri P Mikhailidis
Aug 6, 2015·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·Dylan S MackayPeter J H Jones
Dec 3, 2016·Archives of Endocrinology and Metabolism·Raquel Cristina L A CoelhoJosefina Bressan
Aug 16, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Vineeta SharmaRobert O Ryan
Aug 31, 2018·The Open Cardiovascular Medicine Journal·Vana KolovouGenovefa Kolovou
Sep 4, 2012·Current Cardiology Reports·Niina Matikainen, Marja-Riitta Taskinen
Jul 25, 2013·Current Cardiology Reports·Tanya E Keenan, Daniel J Rader
Jan 6, 2018·Expert Review of Clinical Pharmacology·Niki KatsikiDimitri P Mikhailidis
Jun 14, 2013·International Journal of Clinical Practice·A S Wierzbicki
Apr 15, 2014·Clinical Pharmacology and Therapeutics·F H RachedA Kontush
Oct 19, 2013·Expert Review of Cardiovascular Therapy·Shirya Rashid, John J P Kastelein
Jan 1, 2013·Journal of Drug Assessment·Niki KatsikiAsterios Karagiannis
Nov 6, 2012·Fertility and Sterility·María F HeberAlicia B Motta

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.